Advertisement

Psychopharmacology

, Volume 235, Issue 4, pp 1273–1282 | Cite as

Neurocognitive and behavioural performance of healthy volunteers receiving an increasing analgesic-range infusion of ketamine

  • Amie Hayley
  • Maja Green
  • Luke Downey
  • Michael Keane
  • Panagiota Kostakis
  • Yahya Shehabi
Original Investigation

Abstract

Background

The acute and delayed effect of analgesic-range doses of ketamine on neurocognitive and behavioural outcomes is understudied. Using a non-controlled open-labelled design, three (1-h duration) increasing intravenous (IV) ketamine infusions comprising (i) 30 mg bolus of ketamine + 8 mg/h IV infusion, (ii) 12 mg/h IV infusion and (iii) 20 mg/h infusion were administered to 20 participants (15 male, 5 female, mean age = 30.8 years). Whole-blood ketamine and norketamine concentrations were determined at each treatment step and post-infusion.

Methods

The Cambridge Neuropsychological Test Automated Battery (CANTAB) was used to assess reaction/movement time (RTI, Simple and 5-Choice), visuospatial working memory (SWM), spatial planning (SOC) and subjective effects (visual analogue scale; VAS) during treatment and at post-treatment.

Results

Significant main effects were reported for time (dose) on CANTAB RTI 5-Choice reaction (F(4,18) = 3.41, p = 0.029) and movement time (F(4,18) = 4.42, p = 0.011), SWM (F(4,18) = 4.19, p = 0.014) and SOC (F(4,18) = 4.13, p = 0.015), but not RTI Simple reaction or movement time. Post hoc analyses revealed dose-dependent effects for both RTI 5-Choice reaction and movement time (all p < 0.05). Post-treatment performance on all neurocognitive and behavioural tasks returned to baseline levels. Regression analyses revealed a weak positive linear association between SWM ‘strategy’ score (R2 = 0.103, p < 0.001), all performance-based CANTAB VAS items (R2 range 0.005–0.137, all p < 0.05) and ketamine blood concentrations.

Discussion

The open-label, non-controlled trial design somewhat precludes the ability to adequately account for random treatment effects. Notwithstanding, these results suggest that analgesic doses of ketamine produce acute, selective, dose-dependent deficits in higher-order neurocognitive and behavioural domains.

Keywords

Ketamine Neurocognitive Behavioural Intravenous Therapeutic 

Notes

Compliance with ethical standards

The research was approved by Monash Health Human Research Ethics committee (approval number: HREC/16/MonH/240). All participants provided written informed consent prior to commencing any study procedures. This study was registered on the Australia and New Zealand Clinical Trials registry (www.anzctr.com.au); trial number ACTRN12616001485426.

Conflict of interest

Dr. Amie Hayley is supported by a National Health and Medical Council (NHMRC) Peter Doherty Biomedical Early Career Research Fellowship (APP1119960). A/Prof Downey is supported by an NHMRC R.D. Wright Biomedical Career Development Fellowship (CDF: 2017-2020). Dr. Green, Dr. Keane, Ms. Kostakis and Prof Shehabi declare no potential conflicts of interest.

References

  1. Aberl F, VanDine R (2005) Saliva and sweat testing with Drugwipe®. In: Wong RC, Tse HY (eds) Drugs of abuse: body fluid testing. Humana Press, Totowa, pp 161–175.  https://doi.org/10.1007/978-1-59259-951-6_10 CrossRefGoogle Scholar
  2. Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 79(2):565–575.  https://doi.org/10.1111/j.1476-5381.1983.tb11031.x CrossRefPubMedPubMedCentralGoogle Scholar
  3. Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Med 47(3):211–218.  https://doi.org/10.1111/j.2044-8341.1974.tb02285.x Google Scholar
  4. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP (1998) Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88(1):82–88.  https://doi.org/10.1097/00000542-199801000-00015 CrossRefPubMedGoogle Scholar
  5. Bristow A, Orlikowski C (1989) Subcutaneous ketamine analgesia: postoperative analgesia using subcutaneous infusions of ketamine and morphine. Ann R Coll Surg Engl 71(1):64–66PubMedPubMedCentralGoogle Scholar
  6. Carter LP, Kleykamp BA, Griffiths RR, Mintzer MZ (2013) Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers. Psychopharmacology 226(1):53–63.  https://doi.org/10.1007/s00213-012-2883-x CrossRefPubMedGoogle Scholar
  7. Clements JA, Nimmo WS (1981) Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth 53(1):27–30.  https://doi.org/10.1093/bja/53.1.27 CrossRefPubMedGoogle Scholar
  8. Crisp BR, Swerissen H, Duckett SJ (2000) Four approaches to capacity building in health: consequences for measurement and accountability. Health Promot Int 15(2):99–107.  https://doi.org/10.1093/heapro/15.2.99 CrossRefGoogle Scholar
  9. Ghoneim MM, Hinrichs JV, Mewaldt SP, Petersen RC (1985) Ketamine: behavioral effects of subanesthetic doses. J Clin Psychopharmacol 5(2):70–77.  https://doi.org/10.1097/00004714-198504000-00003 CrossRefPubMedGoogle Scholar
  10. Guillermain Y, Micallef J, Possamaï C, Blin O, Hasbroucq T (2001) N-methyl-d-aspartate receptors and information processing: human choice reaction time under a subanaesthetic dose of ketamine. Neurosci Lett 303(1):29–32.  https://doi.org/10.1016/S0304-3940(01)01695-0 CrossRefPubMedGoogle Scholar
  11. Harborne GC, Watson FL, Healy DT, Groves L (1996) The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers. J Psychopharmacol 10(2):134–140.  https://doi.org/10.1177/026988119601000208 CrossRefPubMedGoogle Scholar
  12. Hirota K, Lambert DG (1996) Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth 77(4):441–444.  https://doi.org/10.1093/bja/77.4.441 CrossRefPubMedGoogle Scholar
  13. Honey RAE et al. (2003) Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory. Neuropsychopharmacology 28: doi: https://doi.org/10.1038/sj.npp.1300272
  14. Jouguelet-Lacoste J, La Colla L, Schilling D, Chelly JE (2015) The use of intravenous infusion or single dose of low-dose ketamine for postoperative analgesia: a review of the current literature. Pain Med 16(2):383–403.  https://doi.org/10.1111/pme.12619 CrossRefPubMedGoogle Scholar
  15. Jurado MB, Rosselli M (2007) The elusive nature of executive functions: a review of our current understanding. Neuropsychol Rev 17(3):213–233.  https://doi.org/10.1007/s11065-007-9040-z CrossRefPubMedGoogle Scholar
  16. Krystal JH, Bennett A, Abi-Saab D, Belger A, Karper LP, D’Souza DC, Lipschitz D, Abi-Dargham A, Charney DS (2000) Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry 47(2):137–143.  https://doi.org/10.1016/S0006-3223(99)00097-9 CrossRefPubMedGoogle Scholar
  17. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive nmda antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51(3):199–214.  https://doi.org/10.1001/archpsyc.1994.03950030035004 CrossRefPubMedGoogle Scholar
  18. Kurdi MS, Theerth KA, Deva RS (2014) Ketamine: current applications in anesthesia, pain, and critical care. Anesth Essays Res 8(3):283–290.  https://doi.org/10.4103/0259-1162.143110 CrossRefPubMedPubMedCentralGoogle Scholar
  19. Lofwall MR, Griffiths RR, Mintzer MZ (2006) Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults. Exp Clin Psychopharmacol 14(4):439–449.  https://doi.org/10.1037/1064-1297.14.4.439 CrossRefPubMedGoogle Scholar
  20. Lou M-F, Yu P-J, Huang G-S, Dai Y-T (2004) Predicting post-surgical cognitive disturbance in older Taiwanese patients. Int J Nurs Stud 41(1):29–41.  https://doi.org/10.1016/S0020-7489(03)00112-3 CrossRefPubMedGoogle Scholar
  21. Lowe C, Rabbitt P (1998) Test\re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues. Neuropsychologia 36(9):915–923.  https://doi.org/10.1016/S0028-3932(98)00036-0 CrossRefPubMedGoogle Scholar
  22. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, David Missar C, Pickar D, Breier A (1996) NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14(5):301–307.  https://doi.org/10.1016/0893-133X(95)00137-3 CrossRefPubMedGoogle Scholar
  23. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17(3):141–150.  https://doi.org/10.1016/s0893-133x(97)00036-5 CrossRefPubMedGoogle Scholar
  24. Micallef J, Guillermain Y, Tardieu S, Hasbroucq T, Possamaï C, Jouve E, Blin O (2002) Effects of subanesthetic doses of ketamine on sensorimotor information processing in healthy subjects. Clin Neuropharmacol 25:101–106CrossRefPubMedGoogle Scholar
  25. Micallef J, Gavaudan G, Burle B, Blin O, Hasbroucq T (2004) A study of a topiramate pre-treatment on the effects induced by a subanaesthetic dose of ketamine on human reaction time. Neurosci Lett 369(2):99–103.  https://doi.org/10.1016/j.neulet.2004.06.082 CrossRefPubMedGoogle Scholar
  26. Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17(8):2921–2927PubMedGoogle Scholar
  27. Morgan CJA, Curran HV (2006) Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology 188(4):408–424.  https://doi.org/10.1007/s00213-006-0572-3 CrossRefPubMedGoogle Scholar
  28. Morgan CJA, Mofeez A, Brandner B, Bromley L, Curran HV (2003) Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 29(1):208–218.  https://doi.org/10.1038/sj.npp.1300342 CrossRefGoogle Scholar
  29. Mortero RF, Clark LD, Tolan MM, Metz RJ, Tsueda K, Sheppard RA (2001) The effects of small-dose ketamine on propofol sedation: respiration, postoperative mood, perception, cognition, and pain. Anesth Analg 92:1465–1469.  https://doi.org/10.1097/00000539-200106000-00022 CrossRefPubMedGoogle Scholar
  30. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20(2):106–118.  https://doi.org/10.1016/S0893-133X(98)00067-0 CrossRefPubMedGoogle Scholar
  31. Olofsen E, NoppersI NM, Kharasch E, Aarts L, Sarton E, Dahan A (2012) Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. Anesthesiology 117(2):353–364.  https://doi.org/10.1097/ALN.0b013e31825b6c91 CrossRefPubMedPubMedCentralGoogle Scholar
  32. Petrenko AB, Yamakura T, Baba H, Shimoji K (2003) The role of N-methyl-d-aspartate (NMDA) receptors in pain: a review. Anesth Analg 97:1108–1116.  https://doi.org/10.1213/01.ane.0000081061.12235.55 CrossRefPubMedGoogle Scholar
  33. Rao TS, Kim HS, Lehmann J, Martin LL, Wood PL (1989) Differential effects of phencyclidine (PCP) and ketamine on mesocortical and mesostriatal dopamine release in vivo. Life Sci 45(12):1065–1072.  https://doi.org/10.1016/0024-3205(89)90163-X CrossRefPubMedGoogle Scholar
  34. Robbins TW (2002) The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacol 163(3-4):362–380.  https://doi.org/10.1007/s00213-002-1154-7 CrossRefGoogle Scholar
  35. Rogers R, Wise RG, Painter DJ, Longe SE, Tracey I (2004) An investigation to dissociate the analgesic and anesthetic properties of ketamine using functional magnetic resonance imaging. Anesthesiology 100(2):292–301.  https://doi.org/10.1097/00000542-200402000-00018 CrossRefPubMedGoogle Scholar
  36. Shallice T (1982) Specific impairments of planning. Philos Trans R Soc Lond Ser B Biol Sci 298(1089):199–209.  https://doi.org/10.1098/rstb.1982.0082 CrossRefGoogle Scholar
  37. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R (1996) Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29(01):23–26.  https://doi.org/10.1055/s-2007-979537 CrossRefPubMedGoogle Scholar
  38. White PF, Way WL, Trevor AJ (1982) Ketamine—its pharmacology and therapeutic uses. Anesthesiology 56(2):119–136.  https://doi.org/10.1097/00000542-198202000-00007 CrossRefPubMedGoogle Scholar
  39. Wieber J, Gugler R, Hengstmann JH, Dengler HJ (1975) Pharmacokinetics of ketamine in man. Anaesthesist 24(6):260–263PubMedGoogle Scholar
  40. Wong JJ, O’Daly O, Mehta MA, Young AH, Stone JM (2016) Ketamine modulates subgenual cingulate connectivity with the memory-related neural circuit—a mechanism of relevance to resistant depression? PeerJ 4:e1710.  https://doi.org/10.7717/peerj.1710 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Centre for Human Psychopharmacology, Faculty of Health, Arts and DesignSwinburne University of TechnologyHawthornAustralia
  2. 2.Program of Critical Care and Perioperative Medicine, School of Clinical SciencesMonash UniversityMelbourneAustralia
  3. 3.Department of Oncology, Monash Health Translation PrecinctMonash UniversityClaytonAustralia
  4. 4.Institute for Breathing and SleepAustin HospitalMelbourneAustralia
  5. 5.Forensic Science South Australia (FSSA)AdelaideAustralia

Personalised recommendations